Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Retained Earnings (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Retained Earnings for 4 consecutive years, with $65000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 100.01% to $65000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $65000.0, a 100.01% increase, with the full-year FY2025 number at $65000.0, up 100.01% from a year prior.
  • Retained Earnings was $65000.0 for Q4 2025 at Day One Biopharmaceuticals, down from $69000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $69000.0 in Q3 2025 to a low of -$620.4 million in Q2 2025.
  • A 4-year average of -$132.8 million and a median of -$8000.0 in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: plummeted 6156555.56% in 2024, then soared 1250.0% in 2025.
  • Day One Biopharmaceuticals' Retained Earnings stood at -$269.7 million in 2022, then soared by 100.0% to $9000.0 in 2023, then tumbled by 6156555.56% to -$554.1 million in 2024, then skyrocketed by 100.01% to $65000.0 in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Retained Earnings are $65000.0 (Q4 2025), $69000.0 (Q3 2025), and -$620.4 million (Q2 2025).